COMP <GO>
LPCN vs KTTA // NET PROFIT MARGIN
Lipocine Inc. (NASDAQ) VS. Pasithea Therapeutics Corp. (NASDAQ) • 15-METRIC TALLY: LPCN 1
— KTTA 2
■ METRIC PARITY
LAST: $1.52 (+0.66%) • MKT CAP: $12.5M
net-margins
-60.00%
LAST: $0.37 (-5.95%) • MKT CAP: $12.3M
net-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LPCN VS. KTTA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LPCN | KTTA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | KTTA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 34.1 | -3.23 | KTTA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.5M | $12.3M | $181.3K | LPCN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LPCN REV | KTTA REV | LPCN GROSS % | KTTA GROSS % | LPCN FCF | KTTA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.0M | $0 | — | — | -$9.8M | -$15.2M |
| FY 2024 | $11.2M | $0 | — | — | -$1.3M | -$13.9M |
| FY 2023 | -$2.9M | $0 | — | — | -$11.9M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LPCN // BETA —
KTTA // BETA —